Acrivon Therapeutics Inc ACRV
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-11-15 |
| Shares Out. | 42,800,000 |
| Website | acrivon.com/ ↗ |
| Phone | 16172078979 |
| Employees | 76 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$18.0M |
| Free Cash Flow | -$64.1M |
| Total Assets | $99.1M |
| Total Liabilities | $12.4M |
| Equity | $86.7M |
About Acrivon Therapeutics Inc
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics Inc is a publicly traded company under the ticker symbol ACRV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)